Despite early success, Verona's lack of specific 2025 guidance and competition from Dupixent and other drugs raise concerns.

The company’s products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ...

Sales of Anoro Ellipta declined 2%. Key established drug Advair/Seretide sales declined 2%, while sales on Revlar/Breo Ellipta declined 5%. Ventolin sales declined%. In General Medicines ...

Illinois Municipal Retirement Fund increased its stake in Innoviva, Inc. (NASDAQ:INVA – Free Report) by 2.8% in the 4th quarter, according to the company in its most recent Form 13F filing with the ...

Drew Kempel represents the engine of the Patriot Machine. When he goes, so do the Patriots. Kempel has known what he’s good ...

Its biggest competitor is GSK, which also has a new dual bronchodilator Anoro Ellipta. Results from GSK's combination have underwhelmed until now, and failed to show superiority to the older ...

It has been about a month since the last earnings report for GSK (GSK). Shares have added about 8% in that time frame, outperforming the S&P 500. Will the recent positive trend continue leading up to ...

Say Manufacturers Ready To Bridge Impact Of GSK, Others Exit From Nigeria Nigerian Pharmaceutical companies are beginning to ...

Innoviva, Inc. (NASDAQ: INVA) ("Innoviva" or the "Company"), a diversified holding company with a core royalties portfolio, a ...